Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

被引：1
|
作者：
Sartor, A. O.
Oudard, S.
Ozguroglu, M.
Hansen, S.
Machiels, J. H.
Shen, L.
De Bono, J. S.
机构：
[1] Tulane Sch Med, New Orleans, LA USA
[2] George Pompidou European Hosp, Paris, France
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Oncol, Istanbul, Turkey
[4] Odense Univ Hosp, DK-5000 Odense, Denmark
[5] Catholic Univ Louvain, Ctr Canc, Clin Univ St Luc, B-1200 Brussels, Belgium
[6] Sanofi Aventis, Malvern, PA USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CABAZITAXEL PLUS PREDNISONE/PREDNISOLONE SIGNIFICANTLY INCREASES OVERALL SURVIVAL COMPARED TO MITOXANTRONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: FINAL RESULTS WITH UPDATED OVERALL SURVIVAL OF A MULTINATIONAL PHASE III TRIAL (TROPIC)
    Oudard, S. M.
    De Bono, J. S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J.
    Shen, L.
    Gupta, S.
    Sartor, A. O.
    ANNALS OF ONCOLOGY, 2010, 21 : 272 - 272
  • [2] CLINICAL BENEFIT OF CABAZITAXEL PLUS PREDNISONE IN THE TROPIC TRIAL IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO PROGRESSED AFTER DOCETAXEL-BASED TREATMENT
    Tombal, B.
    Oudard, S.
    Ozguroglu, M.
    Hansen, S.
    Kocak, I
    Gravis, G.
    Sartor, A. O.
    Shen, L.
    de Bono, J. S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 335 - 336
  • [3] Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)
    De Bono, J. S.
    Oudard, S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J. H.
    Shen, L.
    Matthews, P.
    Sartor, A. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: ANALYSIS BY AGE GROUP
    Parente, P.
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 61 - 61
  • [5] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    LANCET, 2010, 376 (9747): : 1147 - 1154
  • [6] Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Al Harthy, Munjid
    Petrylak, Daniel P.
    Kim, Joseph W.
    Arlen, Philip M.
    Rosner, Inger
    Theoret, Marc R.
    Cordes, Lisa
    Bilusic, Marijo
    Peer, Cody J.
    Dawson, Nancy A.
    Couvillon, Anna
    Hankin, Amy
    Williams, Moniquea
    Chun, Guin
    Owens, Helen
    Marte, Jennifer L.
    Lee, Min-Jung
    Tomita, Yusuke
    Yuno, Akira
    Trepel, Jane B.
    Lee, Sunmin
    Steinberg, Seth M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2021, 127 (04) : 435 - 444
  • [7] Re: Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-Label Trial
    Beuzeboc, Philippe
    EUROPEAN UROLOGY, 2011, 59 (04) : 658 - 658
  • [8] Re: Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomized Open-Label Trial
    Jocham, Dieter
    Sommerauer, Martin
    EUROPEAN UROLOGY, 2011, 59 (04) : 659 - 659
  • [9] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-Label Trial Editorial Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2011, 185 (06): : 2156 - 2157
12345